The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
16945414
DOI
10.1016/j.leukres.2006.07.021
PII: S0145-2126(06)00283-9
Knihovny.cz E-resources
- MeSH
- Fusion Proteins, bcr-abl genetics MeSH
- beta 2-Microglobulin genetics MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics therapy MeSH
- Adult MeSH
- Glucuronidase genetics MeSH
- DNA, Complementary genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- RNA, Messenger genetics MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Proto-Oncogene Proteins c-abl genetics MeSH
- Gene Expression Regulation, Leukemic MeSH
- RNA, Neoplasm analysis MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Fusion Proteins, bcr-abl MeSH
- beta 2-Microglobulin MeSH
- Glucuronidase MeSH
- DNA, Complementary MeSH
- RNA, Messenger MeSH
- Proto-Oncogene Proteins c-abl MeSH
- RNA, Neoplasm MeSH
We compared the effect of control genes (CG): total Abelson (total-ABL), beta-2-microglobulin (B2M) and beta-glucuronidase (GUS), recommended in the Europe Against Cancer (EAC) program, on real-time BCR-ABL monitoring in patients with chronic myeloid leukemia (CML). We focused on the stability of CG expressions during therapy and the effect of the CGs on BCR-ABL ability to characterize the disease status and disease prognosis, issues that have not been addressed yet. The results showed B2M as a very convenient CG for BCR-ABL monitoring. On the contrary, the widely used total-ABL was not confirmed as appropriate for normalization of gene expression in CML.
References provided by Crossref.org
